Stoke Therapeutics (NASDAQ:STOK) Releases Earnings Results, Beats Expectations By $0.38 EPS

Stoke Therapeutics (NASDAQ:STOK) released its quarterly earnings data on Monday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38, Zacks reports. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million.

Stoke Therapeutics Trading Down 6.6 %

STOK stock opened at $7.74 on Wednesday. The firm’s 50-day moving average is $9.44 and its two-hundred day moving average is $11.30. The company has a market capitalization of $418.56 million, a price-to-earnings ratio of -3.69 and a beta of 0.99. Stoke Therapeutics has a 52 week low of $7.22 and a 52 week high of $17.58.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock worth $143,332 over the last quarter. 11.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on STOK. HC Wainwright reaffirmed a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Chardan Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and a consensus target price of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.